TEL AVIV, Israel, Feb. 08, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat CNS and cognitive disorders, today announced that it will report its financial results for the year ended December 31, 2016 on Wednesday, February 15, at 8:30 am Eastern Time. The company also announced a corporate presentation at the BIO CEO & Investor Conference, being held on February 13-14, 2017 at the Waldorf Astoria in New York City.
| FY2016 Financial Results Conference Call & Webcast | |
| Wednesday, February 15th @ 8:30am Eastern Time | |
| Domestic: | 855-469-0611 |
| International: | 484-756-4341 |
| Conference ID: | 63950344 |
| Webcast: | http://edge.media-server.com/m/p/662vg37q |
| Replays available through March 2, 2017 | |
| Domestic: | 855-859-2056 |
| International: | 404-537-3406 |
| Passcode: | 63950344 |
| BIO CEO & Investor Conference | |
| Tuesday, February 14th at 8:30am Eastern Time | |
| Location: | Waldorf Astoria, New York |
| Webcast: | http://www.veracast.com/webcasts/bio/ceoinvestor2017/54203411117.cfm |
About Alcobra
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of medications to treat CNS and cognitive disorders. For more information, please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.